Overview

Efficacy and Safety of MEDI3506 in Adult Subjects With Atopic Dermatitis

Status:
Recruiting
Trial end date:
2022-03-16
Target enrollment:
Participant gender:
Summary
This is a research study to determine the efficacy and safety of investigational drug MEDI3506 for the treatment of adult subjects with Atopic Dermatitis.
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca